Literature DB >> 1431132

Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen.

F Darcy1, P Maes, H Gras-Masse, C Auriault, M Bossus, D Deslee, I Godard, M F Cesbron, A Tartar, A Capron.   

Abstract

The first part of this work presents the sequence of the first 20 NH2 terminus residues obtained from P30, the major surface Ag of Toxoplasma gondii, purified by HPLC. A synthetic peptide (P30 48-67) has been prepared both in linear form and as a multiple antigenic peptide (MAP) construct. Immunization of mice and rats with the P30 48-67 MAP in the presence of IFA induces high levels of IgG antibodies that recognize both the linear peptide and the MAP construct in ELISA, and P30 in Western blots of NP-40-extracted tachyzoite Ag. Because these sera are negative in immunofluorescence assays with whole tachyzoites, it seems that IgG antibodies induced by P30 48-67 MAP, although recognizing the denatured structure, are unable to recognize the native protein. However, the protective effect of both constructs has then been studied in mice and nude rats. Whereas immunization of mice with the monomeric peptide does not confer any protection against oral infection with 1200 cysts of T. gondii 76K strain (mortality within 11 days), 40% of mice immunized with the MAP construct survived up to 75 days after infection. Nude rats were passively transferred with 5 x 10(4) T lymphocytes from P30 48-67 MAP-immunized Fischer rats before infection with 5 x 10(4) RH strain tachyzoites. They survived up to 40 days after infection and raised an intense IgG antibody response against P30, whereas nude rats transferred with control lymphocytes died within 21 days. This shows that immunization with P30 48-67 MAP also induces an efficient T cell immune response. The present work confirms the recently demonstrated role of P30 in protective immunity and shows the interest of peptide octameric constructions as inducers of partially protective immune responses in toxoplasmosis, as already demonstrated in schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431132

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice.

Authors:  V Letscher-Bru; O Villard; B Risse; M Zauke; J P Klein; T T Kien
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

2.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

3.  Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris.

Authors:  Huaiyu Zhou; Qinmin Gu; Qunli Zhao; Jiaqin Zhang; Hua Cong; Ying Li; Shenyi He
Journal:  Parasitol Res       Date:  2006-10-21       Impact factor: 2.289

4.  Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model.

Authors:  M Haumont; L Delhaye; L Garcia; M Jurado; P Mazzu; V Daminet; V Verlant; A Bollen; R Biemans; A Jacquet
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Discovery of compounds blocking the proliferation of Toxoplasma gondii and Plasmodium falciparum in a chemical space based on piperidinyl-benzimidazolone analogs.

Authors:  Nadia Saïdani; Cyrille Y Botté; Michael Deligny; Anne-Laure Bonneau; Janette Reader; Ronald Lasselin; Goulven Merer; Alisson Niepceron; Fabien Brossier; Jean-Christophe Cintrat; Bernard Rousseau; Lyn-Marie Birkholtz; Marie-France Cesbron-Delauw; Jean-François Dubremetz; Corinne Mercier; Henri Vial; Roman Lopez; Eric Maréchal
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.

Authors:  Valentina Martin; Alicia Supanitsky; Pablo C Echeverria; Silvana Litwin; Tamara Tanos; Adolfo R De Roodt; Eduardo A Guarnera; Sergio O Angel
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

7.  Different subsets of T cells in conjunction with natural killer cells, macrophages, and activated microglia participate in the intracerebral immune response to Toxoplasma gondii in athymic nude and immunocompetent rats.

Authors:  D Schlüter; A Hein; R Dörries; M Deckert-Schlüter
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

8.  A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models.

Authors:  Hayam Mohamed Ezz Eldin; Hanan Hussein Kamel; Abeer Fathy Badawy; Lobna Sadek Shash
Journal:  J Parasit Dis       Date:  2013-11-20

9.  Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.

Authors:  C Bonenfant; I Dimier-Poisson; F Velge-Roussel; D Buzoni-Gatel; G Del Giudice; R Rappuoli; D Bout
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Recombinant SAG1 Antigen to Detect Toxoplasma gondii Specific Immunoglobulin G in Human Sera by ELISA Test.

Authors:  N Jalallou; M Bandepour; H Khazan; A Haghighi; Sh Abdollahi; B Kazemi
Journal:  Iran J Parasitol       Date:  2010-06       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.